Characterization of skin pigment spot apparent in human, comprises comparing expression levels, in skin samples form spot and unwounded adjacent skin, of dermal gene e.g. CTSL2 or LYZ involved in remodeling of the extracellular matrix
BERNERD FRANCOISE,FRANCOISE BERNERD,DUVAL CHRISTINE,CHRISTINE DUVAL,DE LACHARRIERE OLIVIER,OLIVIER DE LACHARRIERE,NOUVEAU STEPHANIE,STEPHANIE NOUVEAU
申请号：
FR1153535
公开号：
FR2974372A1
申请日:
2011.04.22
申请国别(地区):
FR
年份:
2012
代理人:
摘要：
Method of characterization of skin pigment spot apparent or suspected in a human, comprises comparing expression levels, in skin samples form the spot and unwounded adjacent skin, of at least a dermal gene involved in the remodeling of the extracellular matrix, comprising MXRA5, LYZ, CTSL2, PLAU or TIMP1 genes. Independent claims are included for: (1) a method of evaluating the efficacy of a treatment of skin pigment spots comprising comparing expression levels, in skin samples form the spot after such a spot, before and after treatment, of the dermal gene； (2) an in vitro method for evaluating the efficacy of a treatment of skin pigment spots, comprising comparing, before and after treatment, the level of expression in a representative cellular model of the skin, of the dermal gene or the level of expression or activity of the expression product of the selected gene； (3) cosmetic method of treatment or prevention of skin pigment spot of non-pathological human skin comprising modulating the level of expression or activity of the gene, where the modulation is effected through the use of an antisense molecule, an small interfering (si)RNA, a microRNA or a plant extract of Lupinus albusLU10； (4) use of a modulator of the expression level or activity of the expression product of the gene, for cosmetic applications in the treatment of non-pathological skin pigment spots, where the modulator is an antisense molecule, siRNA, a microRNA, a plant extract of Lupinus albusLU10, polypeptide for activating pituitary adenylate cyclase, valsartan, demineralized bone powder, sodium phenylacetate, P-aminobenzamidine, 4-substituted benzo [b] thiophene-2 -carboxamidine (B428), thienopyridine (SR 25989) or notoginsenoside R1； and (5) a modulator of the expression level or activity of the expression product of the dermal gene. ACTIVITY : Dermatological. MECHANISM OF ACTION : Gene expression modulator.La présente invention concerne une signature moléculaire des taches pigmentaires cutané
